Full-Time

Medical Affairs Strategy Medical Director

Pain

Posted on 2/27/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

No salary listed

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

In Person

3 days a week on-site in Boston, MA.

MD

Category
Medical, Clinical & Veterinary (1)

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • MD with 10 years of experience or the equivalent combination of education and experience
  • 3+ years’ experience in Medical Affairs within the biotechnology or pharmaceutical industry
  • 3+ years' Clinical experience; pain management or pain adjacent therapeutic areas preferred
  • Knowledge of national healthcare and regulatory environments indispensable
  • Experience in scientific interactions with payer bodies is essential
Responsibilities
  • Provides comprehensive expertise and guidance in the Therapeutic Area and Vertex drugs
  • Develops and maintains professional relationships with local Health Care Professionals, and with local Professional Societies and Patient Advocacy groups
  • Establishes relationships with Thought Leaders to expand research opportunities for Vertex and develops, at local level, advisory, collaborative and/or educational activities aligned to the Vertex strategy
  • Establishes and ensures flawless execution of the local Medical Operational Plan, in accordance with corporate policies and procedures and applicable local laws and regulations
  • Serves as the reference person for medical input and support to the local operations; supports other Vertex functions so that the appropriate patients in the geographic area of responsibility may have access in a safe manner to the benefit of Vertex product(s)
  • Ensures that the scientific data provided locally to Health Care Professionals and Health Care Authorities is provided with a fair and balanced view
  • Acts as the local medical contributor and reviewer/approver of Field Medical Material (proactive and reactive), Promotional Material, Access Material and Medical Information Material for local use
  • Maintains a seamless flow of information within and between the local structure, and communicates medical insights obtained locally from appropriate field interactions to inform local and regional strategy/tactics
  • Develops and maintains high level of industry, regulatory, clinical and scientific knowledge in the Pain therapeutic area
Desired Qualifications
  • Experience driving/leading pre- and post-launch Medical Affairs strategies, with a focus on external engagement with HCPs, KOLs etc
  • Ability to work across a complex matrix organization and influence at all levels
  • Maintains a high level of expertise and judgment in relation to both technical and ethical aspects of a medical director role and responsibilities
  • Ability to both anticipate issues and be flexible and reactive to situations
  • Knowledge and understanding of marketplace dynamics
  • Track-record of ability to plan, initiate and complete projects within allotted time frames & delivering high quality successful results
  • Ability to work within a multi-disciplinary and multi-cultural team on common projects and goals, at national and regional level
  • Capacity to critically analyze current scientific literature
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $3.33 billion, and Vertex raised guidance to $13.2 billion.
  • CASGEVY revenue jumped 151% year over year in Q2 2026 after pediatric expansion.
  • JOURNAVX reached 260 million covered lives, giving Vertex a second commercial growth engine.

What critics are saying

  • August 26, 2026 Lupin won a Delaware ruling against Vertex patents on Kalydeco.
  • Crinetics closes in third quarter 2026, and integration distraction hits execution across five pillars.
  • If CF exclusivity erodes, Vertex loses the cash engine funding its risky diabetes bets.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns the CF standard-of-care, with ALYFTREK and TRIKAFTA driving 2026 growth.
  • August 2026 Crinetics deal adds rare endocrine diseases, expanding Vertex beyond CF dependence.
  • Povetacicept’s November 30, 2026 PDUFA and CASGEVY’s pediatric label show pipeline breadth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Yahoo Finance
Aug 26th, 2026
Vertex Pharmaceuticals up 15% in a month on strong Q2 results and raised guidance

Vertex Pharmaceuticals' stock has climbed 15.4% in a month, buoyed by strong second-quarter results and an improved outlook. The company reported revenues of $3.33 billion, up 12% year over year, and raised its full-year guidance to $13.1–$13.2 billion. Vertex's cystic fibrosis (CF) products generated $6.1 billion in the first half of 2026, growing 8.4% year over year. Its newest CF medicine, Alyftrek, performed particularly well, with second-quarter sales of $573.6 million, up 35% sequentially. The drug surpassed $1 billion in cumulative global revenues in the first half of the year. Vertex holds a leadership position in CF, treating nearly 95% of patients in core markets, with no near-term competitive threats. Label expansions and launches in new geographies are expected to drive continued growth.

Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

INACTIVE